UPDATE 1-Mylan revenue rises on generic drugs boost, reaffirms outlook

May 3 (Reuters) - Drugmaker Mylan NV posted a 17 percent rise in quarterly revenue, helped by higher generic drug sales, and stood by its full-year revenue and adjusted profit guidance.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.